0.20Open0.15Pre Close49 Volume163 Open Interest7.50Strike Price721.00Turnover98.92%IV31.48%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0688Delta0.0450Gamma108.00Leverage Ratio-0.0069Theta-0.0006Rho-7.43Eff Leverage0.0039Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet